Table 3. Examples of Rhenium-188-Labeled Therapeutic Agents Under Development using the Alumina-Based Tungsten-188/Rhenium-188 Generator Available from the Nuclear Medicine Program, Oak Ridge National Laboratory (*ORNL*) (March 2005)

Application	Agent	Principal Investigators/Institution	Comment/Status
Peptides for Tumor Therapy	***Re-188-Peptides***	Diatide, Inc., Londonderry, New Hampshire York Medical, Inc., Ontario, Canada Resolution Pharmaceuticals, Ontario, Canada	Peptide for lung tumor therapy - Animal Data Promising - Initial Phase I Clinical trials complete 2002 Peptides for tumor therapy - Being developed with MURR
Bispecific Antibodies for Tumor Therapy	*Antibodies*	Immunmoedics, Inc., Morris Plains, NY	With "Bifunctional" antibody - Animal Studies Promising
New rhenium-188 "Bifunctional" Radiolabeling Approaches	***Hynic Chelates***	J. Bartis, Ph.D., *et al.,* Dupont Pharm., Boston, MA S. Guhlke, Ph.D, *et al.*, Bonn, Germany	
	Re(V)-HEDP "Kits"	S. Guhlke, Ph.D, *et al.*, Bonn, Germany J. Smalljohan,Ph.D., *et al.*, Vienna, Austria	
Bone pain palliation and tumor therapy	***Re-188-Antibodies***	N. Izago-Escobar, *et al*., Havana, Cuba	"Direct" labeling methods
	Re-188-Antibodies, DMSA and new Phosphonates	Ferro-Flores, Ph.D., *et al.*, National Institute for Nuclear Research. Toluca, Mexico	
Coronary Restenosis Therapy After PTCA	***Coated Angioplasty Balloons***	J. A. Jeong, J.-K. Chung, *et al.*, Seoul National University Hospital	Technology established - animal studies in progress
Magnetic Targeted Carrier ("MTC")	***Activated Carbon Particles***	U. Hafeli, *et al.*, Cleveland Clinic Ferx, Inc., Arvada, Colorado	Rhenium-188-labeled particles are intra arterially injected and localized in target tissue with focusing magnet. Particles are extravasated and permanently trapped in target tissue

FFK: 3/10/05 - File:Re-188-Clinical-Trials